



32281 (2)

GROSS 120

69 JUN 26 4:11:01

RECEIVED

610

EBW

6-27-89

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Salvador Moncada

GROUP : 121

SER. NO. : 07/237,987

EXAMINER: Dentz, B.

FILED : August 29, 1988

FOR : ETHERS

Honorable Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

AMENDMENT

In the specification:

Page 7, line 27, after "including man" insert --Use as an

antihypertensive may be accomplished by administering a pharmaceutical
solution containing the anion of(5Z)-5,6-Didehydro-9-deoxy-6,9 α -epoxy prostaglandin F₁ α --

In the claims:

Claim 35, line 3, cancel "anion".

Claim 37, line 3, after "anion", insert --in a liquid--

REMARKS

The specification amendment is permitted because of original Claim 29 as filed, which indicates for vasodiation and thus antihypertensive use the anion of prostacyclin may be used. Thus, the amendment is not new matter.

It is also quite apparent from the document, which priority is claimed i.e., August 17, 1976, United Kingdom Priority Application, there is disclosure of a "liquid carrier" and at page 5, last 3 lines,